Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial
Published in JAMA, this crossover randomized controlled trial demonstrates glycemic improvements with Dexcom continuous glucose monitoring (CGM) use in patients with T1D treated with multiple daily injections (MDI) insulin therapy and is the first major study to show improvements in key quality of life (QoL) measures.
Study highlights include:
- 0.43% average A1C reduction for CGM group compared to conventional therapy ( blood glucose meter [BGM])
- 3 times many patients in the CGM group showed an average A1C reduction >1.0% compared to conventional therapy
- 80% average decrease in severe hypoglycemia for those in the CGM group (defined as requiring assistance from another person or resulting in unconsciousness)
Source: Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017;317(4):379-387.
The efficacy and safety of the Control-IQ hybrid closed-loop system, powered by Dexcom G6, was evaluated in a multi-centered, randomized, and unblinded study.1 The researchers randomized 168...
Two recently published randomized control trials (RCTs) show the value of Dexcom Continuous Glucose Monitoring (CGM) Systems for teens and young adults with type 1 diabetes (T1D). Both trials’...